276°
Posted 20 hours ago

XLS Medical Appetite Reducer - Appetite Suppressant and Hunger Control for a more Efficient Weight Loss - 60 Capsules, 10 Days Treatment

£9.9£99Clearance
ZTS2023's avatar
Shared by
ZTS2023
Joined in 2023
82
63

About this deal

At the end of the study, significant reductions in mean BMI were seen in both high-dose (1.75 ± 0.83 kg/m 2, ) and low-dose (1.09 ± 0.75 kg/m 2, ) IQP-AE-103 subjects in comparison to the placebo group (0.34 ± 0.77 kg/m 2). Current solutions include Litramine, which was awarded the first Class II medical device certification for a plant-based weight management product in the world, and Tanitol, the first enzyme inhibitor that achieved medical device certification by targeting multiple digestive enzymes.

For beneficial action of fibres on gastrointestinal transit, it is recommended to drink at least 2L of water a day. Slight constipation could occur in case of limited liquid intake. If constipation persists despite adequate fluid intake, please consult your healthcare professional.

How to compress PDF?

As demonstrated by Zaluvida Group’s research and evidenced in InQpharm’s three bmiSMART products, efficacious, safe and easy to apply approaches to weight management do exist. They also allow adaption to individual dietary habits (such as preference for fatty foods or carbohydrate-rich diets) and can help to overcome initial hunger sensations while individuals are transitioning to a healthier diet. Obesity is the fastest growing chronic disease — one that affects people of all ages. Its concomitant health risks are well documented, as is its role in the progression of other diseases, including cardiovascular disease, type 2 diabetes, respiratory problems and osteoarthritis. 1 Stool frequency was assessed based on bowel movements recorded in the subject diaries 3 days a week. Physical activity was recorded using validated International Physical Activity Questionnaire, Short Form (IPAQ-SF) [ 36] during all study visits from visit 2 to visit 6. bmiSMART is the first weight management brand to introduce oral weight management treatments from InQpharm, a Zaluvida Group, which are based on continuous biotech innovations and research. InQpharm NA, the company that brought plant-based, weight-loss system bmiSMART to the US, has announced the publication of a double-blind, placebo-controlled 14-week study in Advancement in Medicinal Plant Research, revealing significant benefits of appetite reduction on weight loss.

The animal and in vitro data used to support the findings of this study are currently under embargo, whereas the research findings are commercialized. Data requests will be considered by the corresponding author 12 months after publication of this article. Conflicts of Interest Direct comparisons of IQP-AE-103 with other weight loss agents that affect dietary fat absorption such as chitosan, Litramine®, or orlistat are difficult for methodological reasons. Ho et al. reported that there were no significant changes from baseline in body weight after 12 weeks of treatment with chitosan [ 39]. A treatment with Litramine® (a proprietary fibre complex) led to 3.8 kg weight loss after 12 weeks of intake [ 17]. As for orlistat (gastric and pancreatic lipase inhibitor), a study by Anderson et al. reported a 3.05 kg weight loss in overweight subjects after 16 weeks of treatment at 180 mg per day [ 40], whereas at higher dose of 360 mg per day, it caused a body weight reduction of 8.3 kg after 12-week period in obese women [ 41]. In summary, the study results provide the first promising evidence that the intake of IQP-AE-103 causes weight loss in overweight and moderately obese subjects in conjunction with a mild hypocaloric diet. The 12-week treatment with IQP-AE-103 also showed very good tolerability. Taken together, IQP-AE-103 can be considered as a safe and effective strategy in fighting obesity with potential benefits in maintaining healthy blood lipids. Data Availability

Check store stock

Objective. This study was performed to determine the efficacy and tolerability/safety of IQP-AE-103 on body weight reduction in overweight to moderately obese adults. Methods. A double-blind, randomized, placebo-controlled trial involved one hundred and eight subjects (BMI between 25 and 35 kg/m 2) that were randomly assigned to either the low-dose or the high-dose IQP-AE-103 group, or the placebo group. Following a 2-week run-in period, subjects received two capsules of investigational product after three daily main meals for 12 weeks. Subjects were instructed to maintain a nutritionally balanced hypocaloric diet according to the individual’s energy requirement. Body weight, body fat, and waist and hip circumference were measured at baseline, and after 2, 4, 8, and 12 weeks. Subjects also rated their feelings of hunger and fullness using visual analogue scales, and food craving on a 5-point scale at the same time intervals. Blood samplings for safety laboratory parameters were taken before and at the end of the study. Results. After 12 weeks of intake, the high-dose IQP-AE-103 group had a significantly greater weight loss compared with the placebo (5.03 ± 2.50 kg vs. 0.98 ± 2.06 kg, respectively; ) and the low-dose group (3.01 ± 2.19 kg; ). The high-dose group experienced a decrease in body fat of 3.15 ± 2.41 kg compared with a decrease of 0.23 ± 2.74 kg for the placebo group ( ). High-dose IQP-AE-103 also decreased the feeling of hunger in 66% subjects. A beneficial effect of IQP-AE-103 on the lipid metabolism was also demonstrated in the subgroup of subjects with baseline total cholesterol levels above 6.2 mmol/L. No side effects related to the intake of IQP-AE-103 were reported. Conclusions. These findings indicate that IQP-AE-103 could be an effective and safe weight loss intervention. This trial is registered with NCT03058367. 1. Introduction It is recommended to take other medications at least one hour before, or four hours after taking Hunger Buddy. Adjust dosage with reference to a healthcare professional. The incidence of adverse side effects being reported was very rare (0.01%). These hypersensitivity reactions were typical of food allergies, like rash, itching, slight swelling and mild gastrointestinal upset. In such cases, treatment should be discontinued. The primary endpoint of this study was the comparison of the mean body weight (kg) change between IQP-AE-103 high dose and placebo after 12 weeks of intervention from baseline, in overweight and moderately obese subjects. The evaluation of the efficacy of IQP-AE-103 was based on the null hypothesis that there are no statistical differences between IQP-AE-103 and placebo in mean reduction of body weight after 12 weeks of treatment. The nonparametric Mann–Whitney U test for independent samples was applied. The testing was carried out by the determination of the rank sum of individual body weight changes. At the end of the study, 97.1% of the subjects in the high-dose IQP-AE-103 group and 85.3% in the low-dose group rated the benefits of the treatment as “good” or “very good” compared with 10% in the placebo group. However, investigator rated the benefit as “good” or “very good” for 94.1% and 85.3% of the subjects in high- and low-dose IQP-AE-103 groups, respectively, compared with 6.7% for placebo subjects. Each bmiSMART product complex has been tested for safety and efficacy, including placebo-controlled, randomised human clinical trials published in peer-reviewed, indexed journals. 3 A spectrum of weight management solutions

Asda Great Deal

Free UK shipping. 15 day free returns.
Community Updates
*So you can easily identify outgoing links on our site, we've marked them with an "*" symbol. Links on our site are monetised, but this never affects which deals get posted. Find more info in our FAQs and About Us page.
New Comment